Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121745 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer
A Phase 1 study, sponsored by Epeius Biotechnologies.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00121745 is a Phase 1 study that was terminated before completion, run by Epeius Biotechnologies. The registered enrollment target is 12 participants.
The verdict
NCT00121745, a Phase 1 study, was terminated before completion, sponsored by Epeius Biotechnologies.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a dose-seeking study that will test the safety of increasing doses of Rexin-G, given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy. Rexin-G is a tumor-targeted gene therapy vector that contains a "killer" gene that blocks the action of the human cyclin G1 gene. Cyclin G1 is a cell cycle control element that plays an important role in cancer growth. When injected into a vein, the Rexin-GTM vector seeks out and accumulates in cancerous tumors, therefore, increasing the concentration of the drug in the cancerous tumors and not in normal neighbouring organs.
Interventions
- GENETIC Rexin-G Dose 1
- GENETIC Rexin-G Dose 2
- GENETIC Rexin-G Dose 3
- GENETIC Rexin-G Dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121745
The ClinicalTrials.gov registry entry for NCT00121745 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epeius Biotechnologies, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rexin-G Dose 1 is the first listed.
NCT00121745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00121745 about?
NCT00121745 is a clinical study titled "Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer". This is a dose-seeking study that will test the safety of increasing doses of Rexin-G, given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy. Rexin-G is a tumor-targeted gene therapy vector that contains a "killer" gene that blocks the a...
What is the current status of trial NCT00121745?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-07. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00121745?
The interventions under investigation include: Rexin-G Dose 1 (GENETIC), Rexin-G Dose 2 (GENETIC), Rexin-G Dose 3 (GENETIC), Rexin-G Dose 4 (GENETIC).
Who is sponsoring clinical trial NCT00121745?
This trial is sponsored by Epeius Biotechnologies, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.